Literature DB >> 26096369

Mifepristone by prescription: a dream in the United States but reality in Australia.

Daniel Grossman1, Philip Goldstone2.   

Abstract

The requirement that mifepristone be dispensed only by physicians in offices, clinics or hospitals - and not by prescription in pharmacies - has likely limited uptake by providers in the United States. However, in several other countries, provision by prescription in pharmacies is allowed, including in Australia. Mifepristone was first registered in Australia in 2012, and in 2015, a composite package including 200 mg mifepristone and four tablets of misoprostol 200 mcg was registered. Both were approved as Schedule 4 medications, which require prescribing by a physician and may be dispensed at pharmacies. As part of the registration for both products, a risk management plan was instituted that has several components. First, physicians must be certified to prescribe mifepristone. General practitioners wishing to become certified must complete online training that includes prescribing requirements and managing the medical abortion process; obstetrician-gynecologists are exempt from the online learning module. Pharmacists must also be certified in order to dispense the medication, although this does not require additional training. When a pharmacist receives a prescription for mifepristone, she or he must confirm through a secure website that the prescriber is certified. In every region of the country, there are more certified prescribers and dispensers of mifepristone than the number of facilities providing abortion care. The experience in Australia demonstrates the feasibility of mifepristone by prescription and should be a model for expanding access to early medical abortion in the United States.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26096369     DOI: 10.1016/j.contraception.2015.06.014

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Requiring physicians to dispense mifepristone: an unnecessary limit on safety and access to medical abortion.

Authors:  Wendy V Norman; Judith A Soon
Journal:  CMAJ       Date:  2016-10-17       Impact factor: 8.262

2.  Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study.

Authors:  Sarah Munro; Edith Guilbert; Marie-Soleil Wagner; Elizabeth S Wilcox; Courtney Devane; Sheila Dunn; Melissa Brooks; Judith A Soon; Megan Mills; Genevieve Leduc-Robert; Kate Wahl; Erik Zannier; Wendy V Norman
Journal:  Ann Fam Med       Date:  2020-09       Impact factor: 5.166

Review 3.  Towards comprehensive early abortion service delivery in high income countries: insights for improving universal access to abortion in Australia.

Authors:  Angela Dawson; Deborah Bateson; Jane Estoesta; Elizabeth Sullivan
Journal:  BMC Health Serv Res       Date:  2016-10-22       Impact factor: 2.655

4.  Medical termination of pregnancy in general practice in Australia: a descriptive-interpretive qualitative study.

Authors:  Angela J Dawson; Rachel Nicolls; Deborah Bateson; Anna Doab; Jane Estoesta; Ann Brassil; Elizabeth A Sullivan
Journal:  Reprod Health       Date:  2017-03-14       Impact factor: 3.223

5.  Medical termination of pregnancy service delivery in the context of decentralization: social and structural influences.

Authors:  Alana Hulme-Chambers; Samantha Clune; Jane Tomnay
Journal:  Int J Equity Health       Date:  2018-11-21

6.  Could implementation of mifepristone address Canada's urban-rural abortion access disparity: a mixed-methods implementation study protocol.

Authors:  Wendy V Norman; Sarah Munro; Melissa Brooks; Courtney Devane; Edith Guilbert; Regina Renner; Tamil Kendall; Judith A Soon; Ashley Waddington; Marie-Soleil Wagner; Sheila Dunn
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

7.  Implementation of mifepristone medical abortion in Canada: pilot and feasibility testing of a survey to assess facilitators and barriers.

Authors:  Courtney Devane; Regina M Renner; Sarah Munro; Édith Guilbert; Sheila Dunn; Marie-Soleil Wagner; Wendy V Norman
Journal:  Pilot Feasibility Stud       Date:  2019-11-08

Review 8.  The impact of provider restrictions on abortion-related outcomes: a synthesis of legal and health evidence.

Authors:  Fiona de Londras; Amanda Cleeve; Maria I Rodriguez; Alana Farrell; Magdalena Furgalska; Antonella F Lavelanet
Journal:  Reprod Health       Date:  2022-04-18       Impact factor: 3.355

9.  Medical abortion offered in pharmacy versus clinic-based settings.

Authors:  Maria I Rodriguez; Alison Edelman; Alyssa Hersh; Pragya Gartoulla; Jillian Henderson
Journal:  Cochrane Database Syst Rev       Date:  2021-06-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.